真核表达载体pLNCX/anti-CD20scFv/IgGFc/CD80/CD28/ζ的构建及其在NIH 3T3细胞株中的表达

目的: 构建pLNCX/anti-CD20scFv/IgGFc/CD80/CD28/ζ的重组真核表达载体，并在NIH 3T3细胞株中表达。方法: 采用DNA重组技术把pBULLET上的CD28-ζcDNA插入到已含anti-CD20 scFv/IgGFc/CD80的真核表达载体pLNCX质粒上，转染NIH 3T3细胞株，经G418筛选细胞，用RT-PCR、流式细胞术检测目的基因表达情况。结果: 经菌落PCR、酶切及一次测序鉴定均证实pLNCX/anti-CD20scFv/IgGFc/CD80/CD28/ζ的成功构建；经RT-PCR法，能够从转染的NIH 3T3细胞中扩增出1条与目的基因大小一致的DNA片段，流式细胞术检测显示该目的基因能够在NIH 3T3细胞中表达目的蛋白。结论: 重组表达载体pLNCX/anti-CD20scFv/IgGFc/CD80/CD28/ζ的构建，并在NIH 3T3细胞株中的成功表达，为该重组质粒转染原代T淋巴细胞从而制备CD20靶向性嵌合锚定T细胞奠定了基础。

Construction of pLNCX/anti-CD20scFv/IgGFc/CD80/CD28/ζ eukaryotic expression vector and expression in NIH 3T3 cells

AIM: To construct a recombinant eukaryotic expression vector pLNCX/anti-CD20scFv/IgGFc/CD80/CD28/ζ and detect its expression in NIH 3T3 cells.METHODS: CD28-ζ cDNA was amplified from the plasmids pBULLET and inserted into pLNCX vector that contained anti-CD20 scFv/IgGFc/CD80 gene.The recombinant plasmids were transfected into NIH 3T3 cells,and resistant clones were obtained by G418 selection.The gene expression of the fusion protein was determined by RT-PCR and FACS.RESULTS: The recombinant eukaryotic vector was constructed successfully,determined by PCR and enzyme digestion analysis.The target gene was amplified from NIH 3T3 cells transfected with the vectors by RT-PCR.The FACS showed that recombinant protein was expressed in NIH 3T3 cells.CONCLUSION: Construction of pLNCX/anti-CD20scFv/IgGFc/CD80/CD28/ζ expression vector and its expression in NIH 3T3 cells lay the foundation for further research of generation of modified T lymphocytes to CD20 positive lymphoma.